Quick Facts

• Cefazolina is indicated for the management of susceptible bacterial infections.
• Its primary therapeutic domains include infections affecting the respiratory tract, urinary tract, skin, and bone.
• The medication is also utilized to help reduce the occurrence of infections following certain surgical procedures.

---

What Cefazolina Treats: Main Uses and Benefits

Cefazolina is a prescription medication utilized to address a variety of infections caused by specific types of susceptible bacteria. As a therapy, it is intended to help bring about the resolution of an existing infection.

Its clinical role encompasses several therapeutic areas. Cefazolina may be used in the management of bacterial infections of the lower respiratory tract, including certain forms of pneumonia. It is also indicated for use against bacterial infections affecting the urinary tract, skin and skin structure, and the biliary tract. Additionally, the drug is used in the context of bone and joint infections, genital infections, and septicemia (bloodstream infections) caused by susceptible organisms.

In addition to treating active infections, Cefazolina has a distinct use in the hospital setting for perioperative prophylaxis. This prophylactic use is intended to help reduce the potential incidence of infection following specific types of surgical procedures. Patients should always consult a healthcare professional for guidance on its use in their particular medical situation.

Who Can and Cannot Use Cefazolina?

This section outlines the official eligibility constraints for Cefazolina (cefazolin) as documented in regulatory sources, defining the specific populations who must not or should not use this medicine.

---

Contraindicated Populations

Cefazolina is contraindicated and must not be used by patients with a history of an immediate hypersensitivity reaction (e.g., severe rash, anaphylaxis) to any of the following:

• Cefazolin
• The cephalosporin class of antibiotics
• Penicillins or any other beta-lactam antibacterial drugs

Age and Condition-Related Restrictions

Population Group	Eligibility Status
Infants under 1 month of age (Neonates/Premature Infants)	Use is not established; safety and effectiveness are not documented.
Patients with Impaired Renal Function	Use is restricted; requires a mandatory reduction or adjustment of the standard dose based on creatinine clearance to prevent drug accumulation and potential toxicity, such as seizures.
Pregnant Individuals	Use only if clearly needed (Pregnancy Category B); animal studies are not always predictive of human risk.
Nursing Mothers	Use with caution, as very low concentrations of cefazolin are known to be excreted in human milk.

Eligibility for Cefazolina is strictly defined by the patient's medical history concerning allergies and the status of their renal function, requiring physicians to confirm these parameters before administration.

The official regulatory documents identify specific interaction patterns for Cefazolina based on pharmacokinetic restrictions and pharmacodynamic risks. Co-administration of the uricosuric agent Probenecid is noted to inhibit the renal tubular secretion of Cefazolina, resulting in higher and more prolonged concentrations of the antibiotic in the bloodstream; for this reason, this combination is formally listed as not recommended.

Pharmacodynamic interactions involve substances that increase specific risks or alter coagulation. Co-administration with Aminoglycoside Antibiotics is associated with an increased risk of additive nephrotoxicity. When Cefazolina is used concurrently with Anticoagulants, there is a documented potential for a fall in prothrombin activity (hypoprothrombinemia), which can enhance the anticoagulant effect and increase the risk of bleeding.

Administrative constraints are also documented. Cefazolina may interfere with the immune response to the Live Typhoid Vaccine, necessitating a mandatory time separation of 24 hours or more between the last dose of the antibiotic and the vaccine. The prescribing information also notes population-specific considerations: patients with renal impairment are at greater risk of increased Cefazolina serum levels, while hepatic impairment or poor nutritional state may increase the risk of the prothrombin activity fall associated with anticoagulants.

Cefazolina, a beta-lactam antibiotic, exerts a bactericidal action by targeting the structural integrity of susceptible bacteria. The action is specific, focusing on the molecular machinery responsible for building and maintaining the bacterial cell wall.

Irreversible Inhibition of Cell Wall Assembly

This mechanism targets the Penicillin-Binding Proteins (PBPs)—enzymes critical for the final cross-linking step of the peptidoglycan polymer. Cefazolin acts as an irreversible inhibitor by binding covalently to and inactivating these PBPs, thereby halting the synthesis of the rigid cell wall. This specific molecular interference immediately compromises the bacterial cell's structural integrity.

Fatal Cascade Leading to Osmotic Lysis

The structural failure caused by PBP inhibition triggers a downstream lytic cascade, where the cell's own autolytic enzymes break down the already defective wall. This rapid deterioration, combined with the extreme internal osmotic pressure, causes the bacterial cell to swell uncontrollably and rupture (lysis). This destructive process is the core physiological consequence, which leads to the bactericidal effect against the pathogen.

Constraints from Bacterial Resistance

The drug's mechanism is biologically constrained by bacterial defense systems, primarily the production of beta-lactamase enzymes. These enzymes hydrolyze the drug's beta-lactam ring, rendering Cefazolin inert before it can bind to the PBP target. The mechanism is also limited by bacteria that possess modified PBP structures with a reduced affinity for the drug.

Cefazolin (Cefazolina) is a cephalosporin antibiotic that is administered parenterally, meaning it is given by injection or infusion. It is supplied as a powder for reconstitution or as a premixed solution for intravenous (IV) injection. Cefazolin is typically administered by a healthcare professional in a clinical setting, such as a hospital or clinic, or by trained personnel for home use following a healthcare provider's instructions.

Administration Methods

Cefazolin can be administered by intravenous (IV) injection or intramuscular (IM) injection after appropriate reconstitution and dilution.

• Intravenous Infusion: Cefazolin is often administered by intravenous infusion over a period of approximately 30 minutes.
• Intramuscular Injection: If administered intramuscularly, the injection should be given into a large muscle mass.

Dosage and Duration

The dosage, frequency, and duration of Cefazolin treatment are determined by your healthcare provider and depend on the type and severity of the infection being treated, your age, weight (for pediatric patients), and your kidney function.

Type of Use	General Adult Frequency	Common Adult Dose Range
Treatment of Infection (Moderate to Severe)	Every 6 to 8 hours	500 mg to 1 gram
Perioperative Prophylaxis	30 minutes to 1 hour prior to surgery	1 gram to 2 grams

It is essential to finish the full course of treatment prescribed by your doctor, even if your symptoms begin to improve sooner. Stopping the medication prematurely may lead to the return of the infection or the development of drug-resistant bacteria. Always inspect the solution for particulate matter or discoloration before use; if present, the solution should be discarded.

Research Evidence / Overview of Studies for Cefazolina

The research evidence for Cefazolina is based on clinical trials and studies conducted over several decades, and this body of evidence is summarized by regulatory and scientific sources for specific uses. This overview describes the research that has been conducted and what remains uncertain, based only on findings reported by regulatory and scientific sources.

---

Evidence for Preventing Infection After Surgery (Perioperative Prophylaxis)

Studies examining Cefazolina in the context of infection incidence following various surgical procedures form a major part of the evidence. Research involves various adult populations undergoing procedures such as cardiac, orthopedic, and gynecological surgeries. The evidence is generally described as High due to the prevalence of Randomized Controlled Trials (RCTs) and Meta-analyses.

Findings describe patterns observed in the studies related to the incidence of Surgical Site Infection (SSI) over follow-up durations typically limited to the immediate post-operative period (30–90 days). Research now focuses on specialized questions, such as optimal timing and redosing for patients with high body weight, rather than the initial evaluation of the preventive pattern.

---

Evidence for Treating Acute Bacterial Infections

The foundation for treating infections of the respiratory tract, urinary tract, and skin structure consists of older Historical Clinical Trials and Efficacy Studies. These studies examined Cefazolina for conditions associated with acute episodes, primarily focusing on clinical cure rates and the measured rate of microbiological clearance in adult and pediatric patients (1 month and older).

However, the evidence quality varies across studies, and much of the foundational data is decades old. Modern comparative evidence against other currently available therapies is often limited, and follow-up durations were typically restricted to the short-term course of the acute infection.

---

Research Gaps and Areas of Uncertainty

For serious conditions like bloodstream infections (septicemia), the certainty remains low because the evidence is largely observational (non-randomized Cohort Studies). This means that high-certainty comparative evidence is lacking. The data also remains insufficient for certain groups, such as pregnant patients, meaning observed patterns in these precise contexts are not fully established by dedicated clinical trials. Research is ongoing and continually exploring optimal application strategies.

Key Studies & References

1. Effective Antimicrobial Prophylaxis in Surgery: The Relevance and Role of Pharmacokinetics-Pharmacodynamics (Review of PK/PD for Cefazolin)

Common questions about Cefazolina (FAQ)

---

Q: For how long is Cefazolin stable after it is mixed (reconstituted)?

According to the official product information, once Cefazolin is mixed and diluted for use, its stability depends on the storage temperature. The solution is generally stable for up to 24 hours when kept at room temperature (about 25 C or 77 F). If stored under refrigeration (about 5 C or 41 F), the solution's stability extends to, typically, 10 days.

---

Q: What are the common side effects of Cefazolin?

Official regulatory documents list the most commonly observed reactions. These primarily affect the gastrointestinal system, including nausea, vomiting, and diarrhea. Local reactions like pain or inflammation (phlebitis) at the injection site are also common. Severe reactions, such as anaphylaxis (a severe allergic reaction), are documented but are less common.

---

Q: Does Cefazolin interact with other antibiotics, like gentamicin?

Official prescribing information notes that Cefazolin has a documented interaction when used concurrently with aminoglycoside antibiotics, which includes drugs like gentamicin. This combination is associated with an increased risk of additive nephrotoxicity, which means an elevated risk of harm or damage to the kidneys.

---

Q: How long does Cefazolin stay in your system after the last dose?

Studies indicate that the drug is cleared from the body relatively quickly. Following administration, the serum half-life (the time it takes for half of the drug to leave the bloodstream) is approximately 1.8 hours for healthy individuals. The majority of the dose is typically eliminated from the body through the urine within 24 hours.

---

Q: Can Cefazolin cause a false-positive result on a diabetes test?

Yes, regulatory information indicates that Cefazolin may interfere with certain laboratory tests. Specifically, it can cause a false-positive reading for glucose (sugar) in the urine when non-enzyme-based testing methods (like Benedict's solution) are used. The official label notes that this interference does not occur when using enzyme-based testing methods (e.g., CLINISTIX).

---

Q: Can I drive or operate machinery while taking Cefazolin?

Official safety documents report that adverse effects on the nervous system, including seizures or convulsions, have been observed in some patients. This risk is specifically noted to be higher for individuals with impaired kidney function if the dose is not appropriately adjusted. Given the potential for these effects, it is important for individuals to monitor how this medication affects them.

Storage and Disposal of Cefazolin Injection

The dry powder for Cefazolin injection must be stored at Controlled Room Temperature (CRT), maintained between 20 C to 25 C (68 F to 77 F). The product must be stored in its original container, protected from light, and must not be frozen.

Stability After Reconstitution

Storage Environment	Maximum Stability Time
Room Temperature (25 C)	24 hours
Refrigeration (5 C)	96 hours

Handling and Disposal

Cefazolin must be kept out of the reach of children. Unused or expired medication and its packaging must be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Disposal via household waste or wastewater should be avoided unless officially instructed.